UNCY - Unicycive Therapeutics - Stock Forecast

Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

UNCY is currently covered by 2 analysts with an average price target of $8.8. This is a potential upside of $4.18 (90.48%) from yesterday's end of day stock price of $4.62.

Unicycive Therapeutics's activity chart (see below) currently has 13 price targets and 32 ratings on display. The stock rating distribution of UNCY is 100% BUY.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 77.14% with an average time for these price targets to be met of 700.75 days.

Highest price target for UNCY is $7.5, Lowest price target is $7.5, average price target is $7.5.

Most recent stock forecast was given by ED ARCE from HC WAINWRIGHT on 11-Apr-2025. First documented stock forecast 09-Aug-2021.

Best performing analysts who are covering UNCY - Unicycive Therapeutics:

Elemer Piros Ed Arce Jason Mccarthy Bruce Jackson

Currently out of the existing stock ratings of UNCY, 18 are a BUY (100%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$7.5

$2.49 (49.70%)

$7.5

3 months 4 days ago
(11-Apr-2025)

2/7 (28.57%)

$6.95 (1263.64%)

424

Buy

7 months 23 days ago
(22-Nov-2024)

4/4 (100%)

$2.09 (229.67%)

584

Buy

$5

$-0.01 (-0.20%)

$5

2 years 15 days ago
(30-Jun-2023)

4/5 (80%)

$3.72 (290.63%)

782

Buy

$6

$0.99 (19.76%)

$3

2 years 4 months 6 days ago
(09-Mar-2023)

2/2 (100%)

$3.94 (191.26%)

1013

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is UNCY (Unicycive Therapeutics) average time for price targets to be met?

On average it took 700.75 days on average for the stock forecasts to be realized with a an average price target met ratio 77.14

Which analyst has the current highest performing score on UNCY (Unicycive Therapeutics) with a proven track record?

ELEMER PIROS

Which analyst has the current lower performing score on UNCY (Unicycive Therapeutics) with a proven track record?

BRUCE JACKSON

Which analyst has the most public recommendations on UNCY (Unicycive Therapeutics)?

Elemer Piros has 6 price targets and 6 ratings on UNCY

Which analyst is the currently most bullish on UNCY (Unicycive Therapeutics)?

Ed Arce with highest potential upside - $2.49

Which analyst is the currently most reserved on UNCY (Unicycive Therapeutics)?

Elemer Piros with lowest potential downside - -$0.01

Unicycive Therapeutics in the News

Unicycive Therapeutics to Present at the H.C. Wainwright 4th Annual Kidney Virtual Conference

LOS ALTOS, Calif., July 07, 2025 (GLOBE NEWSWIRE) — Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that Shalabh Gupta, M.D., Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 4th Annual Kidney Virtual Conference on Monday,...

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?